BARCELONA, September 14, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ...

In the early 20th century, a German chemist named Julius Bredt studied double bonds in bicyclic molecules, which are a group of chemicals that contain two ring-shaped structures attached together.

Bicycle Therapeutics has developed a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, and will gain funding for phase 1 and phase 1b clinical trial ...